Clinical Trials Logo

Clinical Trial Summary

This study is an extension to the completed first-in-human C1091001 study (NCT03170609) and is to evaluate the safety and immunogenicity of a single booster vaccine dose of GBS6, administered approximately 2 years or more after a primary GBS6 dose, to healthy adult males and nonpregnant women. The study will determine whether individuals who received a primary dose of GBS6 have additional benefit following a booster dose.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04258995
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date February 11, 2020
Completion date September 15, 2020

See also
  Status Clinical Trial Phase
Completed NCT05782179 - Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants Phase 1
Completed NCT03170609 - A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age Phase 2
Recruiting NCT05726006 - Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.